Citius Oncology (CTOR) Stock: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.92
0.01 (0.82%)
▲
5d:
+15.82%
30d:
+13.06%
90d:
+32.49%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CTOR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CTOR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.92, which is considered extended relative to its 30-day fair value range of $0.73 to $0.87. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.2) compared to its historical average (4.4). At these levels, the market is pricing in 28.0% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.72, while resistance sits at $0.96.
Market Sentiment: CTOR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+336.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.72, while resistance sits at $0.96.
Market Sentiment: CTOR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+336.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.73 -
$0.87
Company Quality Score
27/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price extended above range (+5.5% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 336.0% below Wall St target ($4.00)
- BEARISH: Market expects 28.0% growth - appears too optimistic based on history
- WARNING: Composite score 27/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.73 -
$0.87
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.72
Resistance Level
$0.96
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.17
Wall Street Target
$4.00
(+336.0%)
Valuation Premium vs History
+28.0% premium
PE vs Historical
9.2 vs 4.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+28.0%
(market-implied from PE analysis)
1-Year Target
$1.17
(+28%)
2-Year Target
$1.50
(+64%)
3-Year Target
$1.92
(+110%)
3-Yr Target (if PE normalizes)
(PE: 9→4)
PE COMPRESSION
$0.92
(+1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: September 13, 2026 10:45 PM ET
Data refreshes hourly during market hours. Next update: 11:45 PM
Data refreshes hourly during market hours. Next update: 11:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |